Interpace Biosciences, Inc. announced adjusting revenue guidance for the year 2019 and provides revenue guidance for the full year 2020. The company is adjusting its 2019 annual net revenue guidance to between $28 and $32 million as the company continue to transition the BioPharma business and prepare for first full year together. The company is also confirming top-line revenue guidance of $50 million for 2020.